|Brand name(s), other common name(s)||Arzerra®|
|Drug type||Monoclonal antibody|
|How the drug is given||Intravenously (IV)|
Indications and Usage
Ofatumumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. It is also approved for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL. It is approved in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.
Side effects needing medical attention
Fever; cough; diarrhea; rash; neutropenia (abnormally low white blood count); fatigue; pneumonia; anemia; trouble breathing; nausea; infusion reactions; and upper respiratory tract infection.
In patients with prior hepatitis B (HBV) infection, HBV reactivation may occur when the body's immune system is impaired.